Therapy of multiple myeloma

Multiple Myeloma (MM) is characterised by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunoglobulin. The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40%-60% and in a median survival time of app...

Full description

Saved in:
Bibliographic Details
Main Authors: Goldschmidt, Hartmut (Author) , Cremer, Friedrich Walter (Author) , Möhler, Thomas (Author) , Krämer, Alwin (Author) , Görner, Martin (Author) , Egerer, Gerlinde (Author) , Ho, Anthony Dick (Author)
Format: Article (Journal)
Language:English
Published: 01 September 2002
In: The Chinese-german journal of clinical oncology
Year: 2002, Volume: 1, Issue: 3, Pages: 141-144
ISSN:1613-9089
DOI:10.1007/BF02851708
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/BF02851708
Get full text
Author Notes:H. Goldschmidt, F.W. Cremer, Th. Möhler, A. Krämer, M. Görner, G. Egerer, A.D. Ho

MARC

LEADER 00000caa a22000002c 4500
001 1789449839
003 DE-627
005 20230426075745.0
007 cr uuu---uuuuu
008 220211s2002 xx |||||o 00| ||eng c
024 7 |a 10.1007/BF02851708  |2 doi 
035 |a (DE-627)1789449839 
035 |a (DE-599)KXP1789449839 
035 |a (OCoLC)1341441501 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
245 1 0 |a Therapy of multiple myeloma  |c H. Goldschmidt, F.W. Cremer, Th. Möhler, A. Krämer, M. Görner, G. Egerer, A.D. Ho 
264 1 |c 01 September 2002 
300 |a 4 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 11.02.2022 
520 |a Multiple Myeloma (MM) is characterised by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunoglobulin. The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40%-60% and in a median survival time of approximately 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Most randomized trials have frailed to show a significant improvement in survival time when combination chemotherapy is used instead of melphalan with or without prednisone. The benefit of maintenance therapy with interferon-alpha has been demonstrated. The toxicity of interferon-alpha, which may reduce the quality of life, should be considered. Recently, myeloma-treatment has been modified. High-dose chemotherapy accompanied by hematopoietic stem-cell support via autologous transplant is recommended up to the age of 65-70 years. First results from a French study comparing single versus double autologous transplantation have shown a benefit in terms of event-free survival for the sequential approach. Vaccinations as an adoptive immuntherapy to treat minimal residual disease are under way. The mortality rate of allogeneic transplantation of hematopoietic stem cells has been reduced in the last 5 years. The use of reduced conditioning regimens or the partial depletion of T cells in peripheral blood stem cell transplants in an effort to decrease transplant related mortality are promising approaches. Thalidomide and its derivates are a new class of agents with independent anti-tumour activity in MM. Encouraging results with this antiangiogenic therapy in phase II trials have been reported. Supportive therapies, such as the treatment of anaemia with erythropoietin, the management of renal failure and the use of bisphosphonates, improve the life quality of MM patients. 
700 1 |a Cremer, Friedrich Walter  |d 1967-  |e VerfasserIn  |0 (DE-588)115550461  |0 (DE-627)691396221  |0 (DE-576)289943752  |4 aut 
700 1 |a Möhler, Thomas  |e VerfasserIn  |0 (DE-588)1014877261  |0 (DE-627)705298051  |0 (DE-576)34979572X  |4 aut 
700 1 |a Krämer, Alwin  |e VerfasserIn  |0 (DE-588)1067780025  |0 (DE-627)819183431  |0 (DE-576)426900820  |4 aut 
700 1 |a Görner, Martin  |d 1964-  |e VerfasserIn  |0 (DE-588)130475378  |0 (DE-627)707497817  |0 (DE-576)298218909  |4 aut 
700 1 |a Egerer, Gerlinde  |e VerfasserIn  |0 (DE-588)105502168X  |0 (DE-627)792516745  |0 (DE-576)167430882  |4 aut 
700 1 |a Ho, Anthony Dick  |d 1948-  |e VerfasserIn  |0 (DE-588)108692477  |0 (DE-627)504904205  |0 (DE-576)19010466X  |4 aut 
773 0 8 |i Enthalten in  |t The Chinese-german journal of clinical oncology  |d Berlin : Springer, 2002  |g 1(2002), 3, Seite 141-144  |h Online-Ressource  |w (DE-627)39223677X  |w (DE-600)2157135-1  |w (DE-576)113949391  |x 1613-9089  |7 nnas  |a Therapy of multiple myeloma 
773 1 8 |g volume:1  |g year:2002  |g number:3  |g pages:141-144  |g extent:4  |a Therapy of multiple myeloma 
856 4 0 |u https://doi.org/10.1007/BF02851708  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220211 
993 |a Article 
994 |a 2002 
998 |g 108692477  |a Ho, Anthony Dick  |m 108692477:Ho, Anthony Dick  |d 910000  |d 910100  |e 910000PH108692477  |e 910100PH108692477  |k 0/910000/  |k 1/910000/910100/  |p 7  |y j 
998 |g 105502168X  |a Egerer, Gerlinde  |m 105502168X:Egerer, Gerlinde  |d 910000  |d 910100  |e 910000PE105502168X  |e 910100PE105502168X  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 130475378  |a Görner, Martin  |m 130475378:Görner, Martin  |d 910000  |d 910100  |e 910000PG130475378  |e 910100PG130475378  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 1067780025  |a Krämer, Alwin  |m 1067780025:Krämer, Alwin  |d 910000  |d 910100  |e 910000PK1067780025  |e 910100PK1067780025  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 1014877261  |a Möhler, Thomas  |m 1014877261:Möhler, Thomas  |d 910000  |d 910100  |e 910000PM1014877261  |e 910100PM1014877261  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 115550461  |a Cremer, Friedrich Walter  |m 115550461:Cremer, Friedrich Walter  |d 910000  |d 910100  |e 910000PC115550461  |e 910100PC115550461  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1789449839  |e 4056017107 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["H. Goldschmidt, F.W. Cremer, Th. Möhler, A. Krämer, M. Görner, G. Egerer, A.D. Ho"]},"person":[{"display":"Goldschmidt, Hartmut","role":"aut","given":"Hartmut","family":"Goldschmidt"},{"display":"Cremer, Friedrich Walter","role":"aut","given":"Friedrich Walter","family":"Cremer"},{"role":"aut","given":"Thomas","display":"Möhler, Thomas","family":"Möhler"},{"family":"Krämer","display":"Krämer, Alwin","role":"aut","given":"Alwin"},{"family":"Görner","given":"Martin","role":"aut","display":"Görner, Martin"},{"role":"aut","given":"Gerlinde","display":"Egerer, Gerlinde","family":"Egerer"},{"family":"Ho","display":"Ho, Anthony Dick","role":"aut","given":"Anthony Dick"}],"recId":"1789449839","origin":[{"dateIssuedKey":"2002","dateIssuedDisp":"01 September 2002"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"4 S."}],"id":{"doi":["10.1007/BF02851708"],"eki":["1789449839"]},"note":["Gesehen am 11.02.2022"],"relHost":[{"pubHistory":["1.2002 - 12.2013; damit Ersch. eingest."],"language":["eng"],"part":{"issue":"3","pages":"141-144","extent":"4","text":"1(2002), 3, Seite 141-144","year":"2002","volume":"1"},"title":[{"title_sort":"Chinese-german journal of clinical oncology","title":"The Chinese-german journal of clinical oncology","subtitle":"organ of Chinese-German, German-Chinese Medical Association"}],"recId":"39223677X","origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"2002","publisher":"Springer","dateIssuedDisp":"2002-2013"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 05.01.15"],"id":{"issn":["1613-9089"],"zdb":["2157135-1"],"eki":["39223677X"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Therapy of multiple myelomaThe Chinese-german journal of clinical oncology"}],"title":[{"title_sort":"Therapy of multiple myeloma","title":"Therapy of multiple myeloma"}],"language":["eng"]} 
SRT |a GOLDSCHMIDTHERAPYOFM0120